Network analysis of HBV‑ and HCV‑induced hepatocellular carcinoma based on Random Forest and Monte Carlo cross‑validation

Zhao,Shan‑Na; Liu,Ling‑Ling; Lv,Zhi‑Ping; Wang,Xiao‑Hua; Wang,Cheng‑Hong

doi:10.3892/mmr.2017.6861

Network analysis of HBV‑ and HCV‑induced hepatocellular carcinoma based on Random Forest and Monte Carlo cross‑validation

Authors:
- Shan‑Na Zhao
- Ling‑Ling Liu
- Zhi‑Ping Lv
- Xiao‑Hua Wang
- Cheng‑Hong Wang
View Affiliations

Affiliations: Department of Clinical Laboratory, Yantaishan Hospital, Yantai, Shandong 264008, P.R. China, Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/mmr.2017.6861
Pages: 2411-2416

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‑associated mortality worldwide. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are two common risk factors for HCC. The majority of patients with HCC present at an advanced stage and are refractory to therapy. It is important to identify a method for efficient diagnosis at early stage. In the present study gene expression profile data, generated from microarray data, were pretreated according to the annotation files. The genes were mapped to pathways of Ingenuity Pathways Analysis. Dysregulated pathways and dysregulated pathway pairs were identified and constructed into individual networks, and a main network was constructed from individual networks with several edges. Random Forest (RF) classification was introduced to calculate the area under the curve (AUC) value of this network. Subsequently, 50 runs of Monte Carlo cross‑validation were used to screen the optimal main network. The results indicated that a total of 4,929 genes were identified in the pathways and gene expression profile. By combining dysregulated pathways with Z<0.05 and dysregulated pathway pairs with Z<0.2, individual networks were constructed. The optimal main network with the highest AUC value was identified. In the HCV group, the network was identified with an AUC value of 0.98, including 41 pairs of pathways, and in the HBV group, the network was identified with an AUC value of 0.94, including eight pairs of pathways. In addition, four pairs were identified in both groups. In conclusion, the optimal networks of HCV and HBV groups were identified with the highest AUC values. The use of these networks is expected to assist in diagnosing patients effectively at an early stage.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Kumar R, Saraswat MK, Sharma BC, Sakhuja P and Sarin SK: Characteristics of hepatocellular carcinoma in India: A retrospective analysis of 191 cases. QJM. 101:479–485. 2008. View Article : Google Scholar : PubMed/NCBI
3	Wong PY, Xia V, Imagawa DK, Hoefs J and Hu KQ: Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health. 13:842–848. 2011. View Article : Google Scholar : PubMed/NCBI
4	Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST and Wong J: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:1164–1171. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ma S, Jiao B and Liu X, Yi H, Kong D, Gao L, Zhao G, Yang Y and Liu X: Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev. 36:157–163. 2010. View Article : Google Scholar : PubMed/NCBI
6	Abou-Alfa GK: Hepatocellular carcinoma: Molecular biology and therapy. Semin Oncol. 33:(6 Suppl 11). S79–S83. 2006. View Article : Google Scholar : PubMed/NCBI
7	Sherman M: Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin Liver Dis. 25:143–154. 2005. View Article : Google Scholar : PubMed/NCBI
8	Attwa MH and El-Etreby SA: Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 7:1632–1651. 2015. View Article : Google Scholar : PubMed/NCBI
9	Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, Wright EC, Everson GT, Lindsay KL, Lok AS, et al: Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol. 43:434–441. 2005. View Article : Google Scholar : PubMed/NCBI
10	Woo HG, Park ES, Cheon JH, Kim JH, Lee JS, Park BJ, Kim W, Park SC, Chung YJ, Kim BG, et al: Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin Cancer Res. 14:2056–2064. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tackels-Horne D, Goodman MD, Williams AJ, Wilson DJ, Eskandari T, Vogt LM, Boland JF, Scherf U and Vockley JG: Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer. 92:395–405. 2001. View Article : Google Scholar : PubMed/NCBI
12	Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 28:3994–4005. 2010. View Article : Google Scholar : PubMed/NCBI
13	Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL and Lampertico P: Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol. 62:956–967. 2015. View Article : Google Scholar : PubMed/NCBI
14	Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL and Chen J: Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 12:171–179. 2013. View Article : Google Scholar : PubMed/NCBI
15	Lee SY, Song KH, Koo I, Lee KH, Suh KS and Kim BY: Comparison of pathways associated with hepatitis B- and C-infected hepatocellular carcinoma using pathway-based class discrimination method. Genomics. 99:347–354. 2012. View Article : Google Scholar : PubMed/NCBI
16	Ahn T, Lee E, Huh N and Park T: Personalized identification of altered pathways in cancer using accumulated normal tissue data. Bioinformatics. 30:i422–i429. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kim BY, Choi DW, Woo SR, Park ER, Lee JG, Kim SH, Koo I, Park SH, Han CJ, Kim SB, et al: Recurrence-associated pathways in hepatitis B virus-positive hepatocellular carcinoma. BMC Genomics. 16:2792015. View Article : Google Scholar : PubMed/NCBI
18	Yoon SY, Kim JM, Oh JH, Jeon YJ, Lee DS, Kim JH, Choi JY, Ahn BM, Kim S, Yoo HS, et al: Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol. 29:315–327. 2006.PubMed/NCBI
19	Parkinson H, Kapushesky M, Shojatalab M, Abeygunawardena N, Coulson R, Farne A, Holloway E, Kolesnykov N, Lilja P, Lukk M, et al: ArrayExpress-a public database of microarray experiments and gene expression profiles. Nucleic Acids Res. 35:(Database Issue). D747–D750. 2007. View Article : Google Scholar : PubMed/NCBI
20	Bolstad BM, Irizarry RA, Astrand M and Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
21	Benjamini Y and Yekutieli D: Quantitative trait Loci analysis using the false discovery rate. Genetics. 171:783–790. 2005. View Article : Google Scholar : PubMed/NCBI
22	Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al: Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science. 286:531–537. 1999. View Article : Google Scholar : PubMed/NCBI
23	Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rougé C, Ursule L, Nguyen C, Bibeau F, Rodriguez C and Theillet C: Genetic profiling of chromosome 1 in breast cancer: Mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer. 95:1439–1447. 2006. View Article : Google Scholar : PubMed/NCBI
24	Burgette LF and Reiter JP: Multiple imputation for missing data via sequential regression trees. Am J Epidemiol. 172:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
25	Tsuji S, Midorikawa Y, Takahashi T, Yagi K, Takayama T, Yoshida K, Sugiyama Y and Aburatani H: Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer. 106:126–132. 2012. View Article : Google Scholar : PubMed/NCBI
26	Colaprico A, Cava C, Bertoli G, Bontempi G and Castiglioni I: Integrative analysis with Monte Carlo Cross-Validation reveals miRNAs regulating pathways Cross-talk in aggressive breast cancer. Biomed Res Int. 2015:8313142015. View Article : Google Scholar : PubMed/NCBI
27	Saito K, Shirasago Y, Suzuki T, Aizaki H, Hanada K, Wakita T, Nishijima M and Fukasawa M: Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus. J Virol. 89:2220–2232. 2015. View Article : Google Scholar : PubMed/NCBI
28	Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, Chien D, Selby MJ and Ou J: Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J. 20:3840–3848. 2001. View Article : Google Scholar : PubMed/NCBI
29	Ratinier M, Boulant S, Combet C, Targett-Adams P, McLauchlan J and Lavergne JP: Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1. J Gen Virol. 89:1569–1578. 2008. View Article : Google Scholar : PubMed/NCBI
30	Carbajo-Pescador S, Ordoñez R, Benet M, Jover R, García-Palomo A, Mauriz JL and González-Gallego J: Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 109:83–91. 2013. View Article : Google Scholar : PubMed/NCBI
31	Brustolim D, Ribeiro-dos-Santos R, Kast RE, Altschuler EL and Soares MB: A new chapter opens in anti-inflammatory treatments: The antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 6:903–907. 2006. View Article : Google Scholar : PubMed/NCBI
32	Chen WC, Lai HC, Su WP, Palani M and Su KP: Bupropion for interferon-alpha-induced depression in patients with hepatitis C viral infection: An open-label study. Psychiatry Investig. 12:142–145. 2015. View Article : Google Scholar : PubMed/NCBI
33	Packer L, Tritschler HJ and Wessel K: Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med. 22:359–378. 1997. View Article : Google Scholar : PubMed/NCBI
34	Na MH, Seo EY and Kim WK: Effects of alpha-lipoic acid on cell proliferation and apoptosis in MDA-MB-231 human breast cells. Nutr Res Pract. 3:265–271. 2009. View Article : Google Scholar : PubMed/NCBI